Webnonsurgical therapy, argatroban and bivalirudin may be assayed using the PTT. The target therapeutic range is 1.5–3.0 times the mean of the laboratory-established reference … WebContrary to argatroban, more dose adaptations were required in order to achieve a therapeutic TT 5 (median 12.5 per patient, range 3–15) and the median first therapeutic bivalirudin dosage was almost 3 times higher …

Anticoagulation Monitoring During Cardiac Procedures

WebJun 11, 2024 · Variability and therapeutic ranges differ between clinical sites and should be individualized. Anti-factor Xa levels. For unfractionated heparin (UFH) management, ... Bivalirudin is a small peptide (~2400 Daltons) DTI that inhibits reversibly binds thrombin. The half-life is 20–30 minutes but is prolonged in renal failure up to 240 minutes. WebFor example, if the aPTT was not therapeutic 4 hours after starting bivalirudin therapy, but became therapeutic at 8 hours, then the level would be assumed to have been out of range for 4 hours (hours 4–8). Analysis of %TTR for time frame A was independently performed by two study investigators to appropriately validate the data. marco feger

CLEVELAND CLINIC ANTICOAGULATION MANAGEMENT …

WebDespite a rather narrow therapeutic dosing range and a lack of a ready antidote, bivalirudin is more widely used in percutaneous coronary interventional procedures in place of heparin because it has a more predictable anticoagulant effect ().Several studies have shown that standard activated clotting time (ACT) tests based on kaolin do not accurately … WebBivalirudin: therapeutic anticoagulation Due to the liver injury that may be seen in patients with COVID-19, bivalirudin is the preferred direct thrombin inhibitor for the treatment of HIT, enoxaparin failure, or patients receiving extracorporeal membrane oxygenation (ECMO). CrCl (ml/min) Bivalirudin Initial dose (mg/kg/hour) > 60 0.15 +/- 0.1 WebJun 19, 2024 · If initiating bivalirudin during PCI: Initial: 0.75 mg/kg bolus immediately prior to procedure, followed immediately by 1.75 mg/kg/hour for the duration of procedure. During the procedure, may determine ACT 5 minutes after bolus dose and administer an additional bolus of 0.3 mg/kg if necessary. cssci ei